| Performance and Usability Evaluation of the Atomo HIV Self-Test (NCT03755986) | Holdsworth House Medical Practice | 2016-10-01 |
| Retention in PrEP Care for African American MSM in Mississippi (NCT03256435) | Brown University | 2016-09-07 |
| Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis (NCT02583048) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-15 |
| Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa (NCT04205721) | University of North Carolina, Chapel Hill | 2016-08-08 |
| Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection (NCT02664415) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-01 |
| An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) (NCT02831673) | ViiV Healthcare | 2016-07-21 |
| An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) (NCT02831764) | ViiV Healthcare | 2016-07-18 |
| Evaluation of Low-dose Darunavir in a Switch Study (NCT02671383) | Willem Daniel Francois Venter | 2016-06-30 |
| Safety and Immune Response to a Clade C DNA HIV Vaccine (NCT02997969) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-06-21 |
| A Waiting Room-Delivered Video to Enhance Clinical Outcomes Among Persons Living With HIV (NCT03508310) | Centers for Disease Control and Prevention | 2016-06-01 |
| Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults (NCT02475655) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-16 |
| Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) (NCT02741557) | ViiV Healthcare | 2016-05-11 |
| Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (NCT02568215) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-01 |
| Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) (NCT02519777) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-21 |
| Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (NCT02716675) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-06 |
| Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection (NCT02588820) | David Garcia Cinca | 2016-04-01 |
| Provision of HIV Self-Test Kit to Emergency Department Patients (NCT03021005) | Johns Hopkins University | 2016-03-01 |
| Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults (NCT02654080) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-03-01 |
| A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD) (NCT02674581) | ViiV Healthcare | 2016-02-26 |
| The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study (NCT04087239) | University of Zimbabwe | 2016-01-26 |
| Taste Properties of HIV Inhibitor (NCT02608918) | ViiV Healthcare | 2016-01-05 |
| Older HIV-infected Adults and Drug Interactions: French Cross-sectional Study (NCT03416881) | University Hospital, Caen | 2016-01-01 |
| Aberrant Myeloid Lineage Differentiation in HIV/AIDS Patients (NCT05808803) | Zhongnan Hospital | 2016-01-01 |
| Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (NCT03033836) | Fundación Huésped | 2015-12-01 |
| Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates (NCT02578277) | ViiV Healthcare | 2015-11-09 |
| Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations (NCT02354053) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2015-11-01 |
| Smart Linkage-to-HIV Care Via a Smartphone App (NCT02756949) | World Bank | 2015-10-01 |
| Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women (NCT04045652) | Indiana University | 2015-09-21 |
| Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (NCT02194998) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-09-16 |
| Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) (NCT02411539) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-25 |
| Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection (NCT02527460) | National Institute of Neurological Disorders and Stroke (NINDS) | 2015-08-17 |
| Randomised Study Comparing Two HIV Screening Strategies (NCT03038724) | University of Lausanne Hospitals | 2015-08-11 |
| Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption (NCT02463227) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-01 |
| Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria (NCT02447159) | University of California, San Francisco | 2015-08-01 |
| Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults (NCT02431767) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-01 |
| Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology (NCT02527941) | University of Toronto | 2015-08-01 |
| Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment (NCT02354937) | ViiV Healthcare | 2015-07-13 |
| Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults (NCT02386098) | ViiV Healthcare | 2015-07-08 |
| Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants (NCT02256631) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-06-30 |
| A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers (NCT02354950) | ViiV Healthcare | 2015-06-22 |
| Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen (NCT02478632) | ViiV Healthcare | 2015-06-12 |
| Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048 (NCT02419456) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-06-01 |
| "Persistence of Neutralizing Antibodies Against Yellow Fever (YF) in HIV-infected Patients" (NCT03591003) | Centre Hospitalier Universitaire Saint Pierre | 2015-06-01 |
| Community Health Workers and Prevention of Mother-to-Child HIV Transmission in Tanzania (NCT03058484) | University of California, Berkeley | 2015-05-01 |
| Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) (NCT02422797) | ViiV Healthcare | 2015-04-21 |
| Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1) (NCT02429791) | ViiV Healthcare | 2015-04-14 |
| Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health (NCT04320186) | University of Alabama at Birmingham | 2015-04-03 |
| ART Drug Dosage Adjustment in HIV-infected Population (NCT02632474) | Shanghai Public Health Clinical Center | 2015-04-01 |
| Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (NCT02213328) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-04-01 |
| Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients (NCT02362503) | ViiV Healthcare | 2015-02-23 |
| Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (NCT02342769) | ViiV Healthcare | 2015-02-19 |
| Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection (NCT02553369) | University Hospital Center of Martinique | 2015-02-01 |
| Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults (NCT02178800) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-01 |
| Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection (NCT02170246) | Yale University | 2015-01-28 |
| Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection (NCT02178592) | ViiV Healthcare | 2015-01-23 |
| A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial (NCT02712489) | Barbara Ensoli, MD, PhD | 2015-01-01 |
| Understanding HIV Susceptibility in the Female Genital Tract (NCT03064425) | Unity Health Toronto | 2015-01-01 |
| ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection (NCT02075593) | ViiV Healthcare | 2014-12-17 |
| Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment (NCT02227238) | ViiV Healthcare | 2014-12-11 |
| Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults (NCT02296541) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-01 |
| Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB (NCT01751568) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-11-12 |
| Study on Pharmacokinetics (NCT02234882) | ViiV Healthcare | 2014-09-05 |
| Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (NCT02116660) | Merck Sharp & Dohme LLC | 2014-09-03 |
| Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age (NCT01975012) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-01 |
| A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults. (NCT01937455) | International AIDS Vaccine Initiative | 2014-09-01 |
| Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV (NCT01852942) | University of Minnesota | 2014-09-01 |
| Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women (NCT01494038) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-19 |
| Evaluation of a Home-based Community Health Worker Program in Rural Eastern Cape, South Africa (NCT03517878) | University of California, Los Angeles | 2014-08-11 |
| Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans. (NCT02206711) | ViiV Healthcare | 2014-08-08 |
| AIDS 347: IL-6 Blockade in Treated HIV Infection (NCT02049437) | Case Western Reserve University | 2014-08-01 |
| Study of Immune Responses Induced by a HIV Vaccine (NCT01933685) | U.S. Army Medical Research and Development Command | 2014-07-03 |
| Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test (NCT02190578) | MedMira Laboratories Inc. | 2014-07-01 |
| Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults (NCT02207920) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-07-01 |
| Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load (NCT01933594) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-05 |
| Rapid Diagnostics for HIV and Hepatitis (NCT02190305) | MedMira Laboratories Inc. | 2014-05-01 |
| Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir (NCT02097108) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2014-05-01 |
| A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (NCT02120352) | ViiV Healthcare | 2014-04-28 |
| Test Albuvirtide in Experienced Patients (NCT02369965) | Frontier Biotechnologies Inc. | 2014-02-19 |
| Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications (NCT01949116) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-01-31 |
| Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection (NCT01780831) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-01-28 |
| Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (NCT02016924) | Gilead Sciences | 2014-01-16 |
| Medication-assisted Treatment for Injecting Drug Users in Vietnam (NCT05368675) | University of Pennsylvania | 2013-12-18 |
| Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (NCT01967940) | Gilead Sciences | 2013-10-25 |
| The Safety and Immunogenicity of a Potential HIV Vaccine (NCT01966900) | Imperial College London | 2013-10-01 |
| A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) (NCT01930045) | Merck Sharp & Dohme LLC | 2013-10-01 |
| Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (NCT01931358) | U.S. Army Medical Research and Development Command | 2013-09-24 |
| Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission (NCT01618305) | Westat | 2013-09-05 |
| Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (NCT01968551) | Gilead Sciences | 2013-09-03 |
| Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B (NCT01923610) | Hospital Clinic of Barcelona | 2013-09-01 |
| Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants (NCT01923311) | Gilead Sciences | 2013-08-26 |
| A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) (NCT01910402) | ViiV Healthcare | 2013-08-22 |
| Seek, Test, Treat, Retain: An Integrated Jail-Prison-Community Model for Illinois (NCT01852877) | University of Illinois at Chicago | 2013-07-01 |
| The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies (NCT01751100) | North Bronx Healthcare Network | 2013-07-01 |
| French CAC-HIV Cohort Study (NCT05563116) | Franck Boccara | 2013-06-01 |
| Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (NCT01854775) | Gilead Sciences | 2013-05-06 |
| Study to Evaluate a HIV Drug for the Treatment of HIV Infection (NCT01803074) | ViiV Healthcare | 2013-04-04 |
| Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers (NCT02604004) | Universidade Federal de Pernambuco | 2013-04-01 |
| Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults (NCT01783977) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-04-01 |
| Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment (NCT01818596) | Gilead Sciences | 2013-03-27 |
| Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (NCT01815736) | Gilead Sciences | 2013-03-27 |